ReviewCancers2021
Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study.Frontiers in immunology · 2022Pooled it
- Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.Journal for immunotherapy of cancer · 2024Trial
- The Relationship Between (Endo)cannabinoids, the Microbiome and Melanoma.Pharmacology research & perspectives · 2026Review
- Integrated Meta-Analysis Identifies Keratin Family Genes and Associated Genes as Key Biomarkers and Therapeutic Targets in Metastatic Cutaneous Melanoma.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Cell Death Modalities in Therapy of Melanoma.International journal of molecular sciences · 2025Review
- Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects.Journal of experimental & clinical cancer research : CR · 2025Review
- Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.JCO precision oncology · 2025Article
- Analysis of Calculated Liver Scores for Long-Term Outcome in 423 Cutaneous Melanoma Patients.Cancers · 2024Article
- Incidence and mortality trends of primary cutaneous melanoma: A 50-year Rochester Epidemiologic Project study.JAAD international · 2024Article
- Hepatic resection for metastatic melanoma in the era of targeted therapy: A case report.International journal of surgery case reports · 2024Article
- Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.NPJ precision oncology · 2024Article
- Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.Cell communication and signaling : CCS · 2024Article
- A Review of Current and Pipeline Drugs for Treatment of Melanoma.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.Journal of translational medicine · 2024Observational
- A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.Communications biology · 2024Article
- GREB1 isoform 4 is specifically transcribed by MITF and required for melanoma proliferation.Oncogene · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This decade has brought significant survival improvement in patients with metastatic melanoma with targeted therapies and immunotherapies. As our understanding of the mechanisms of action of these therapeutics evolves, even more impressive therapeutic success is being achieved through various combination strategies, including combinations of different immunotherapies as well as with other modalities. This review summarizes prospectively and retrospectively generated clinical evidence on modern melanoma therapy, focusing on immunotherapy and targeted therapy with BRAF kinase inhibitors and MEK kinase inhibitors (BRAF/MEK inhibitors), including recent data presented at major conference meetings. The combination of the anti-PD-1 directed monoclonal antibody nivolumab and of the CTLA-4 antagonist ipilimumab achieves unprecedented 5-year overall survival (OS) rates above 50%; however, toxicity is high. For PD-1 monotherapy (nivolumab or pembrolizumab), toxicities are in general well manageable. Today, novel combinations of such immune checkpoint inhibitors (ICIs) are under investigation, for example with cytokines and oncolytic viruses (i.e., pegylated interleukin-2, talimogene laherparepvec). Furthermore, current studies investigate the combined or sequential use of ICIs plus BRAF/MEK inhibitors. Several studies focus particularly on poor prognosis patients, as e.g., on anti-PD-1 refractory melanoma, patients with brain metastases, or uveal melanoma. It is hoped, on the road to cure, that these new approaches further improve long term survival in patients with advanced or metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.